Veritas Pharma Files Cannabis Strain Patent for Opioid Analgesics

Veritas Pharma (CSE:VRT; OTC:VRTHF) announced its research arm Cannevert Therapeutics filed a provisional patent application to US Patent and Trademark Office for the use of a specific cannabis strain to enhance the actions of opioid analgesics.
As quoted in the press release:

Veritas CEO, Dr. Lui Franciosi stated, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for patients.”  Dr. Franciosi goes on to say, “This strain could be also potentially useful in addressing the current fentanyl crisis throughout North America.  If we’re targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that clinicians can rely upon.”

Click here to read the full press release.

Source: globenewswire.com